Physician profile
David Wayne Patterson
NPI 1073553525
$6,583.97
in general payments reported to CMS, 2019-2025
23 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,234 · 2022: $2,951 · 2023: $862 · 2024: $86.76 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.02 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.54 | 2021-2025 | |
| Janssen Biotech, INC. | $606.65 | 2021-2025 | Remicade, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $572.89 | 2021-2025 | |
| Leo Pharma INC. | $492.71 | 2021-2023 | Adbry |
| Pfizer INC. | $445.92 | 2021-2023 | |
| Lilly USA, LLC | $443.55 | 2021-2024 | Taltz, Olumiant |
| Amgen INC. | $408.78 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $343.10 | 2021-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $308.85 | 2021-2024 | |
| Journey Medical Corporation | $308.55 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $233.52 | 2021-2025 | Winlevi |
| Incyte Corporation | $206.38 | 2021-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $179.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $174.87 | 2022-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $120.55 | 2021-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $114.02 | 2021-2022 | |
| Biofrontera INC. | $74.94 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $61.77 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $55.96 | 2022-2023 | Vtama |
| Janssen Scientific Affairs, LLC | $52.31 | 2021 | |
| Genentech USA, INC. | $37.21 | 2021-2022 | |
| Allergan, INC. | $18.01 | 2022 | |
| Epi Health, LLC | $15.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.